Evidence map›Paper›PMID 33103132›Full record

ArticleThe Lancet. Microbe2020

Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study.

Anchi Wu, Valia T Mihaylova, Marie L Landry, Ellen F Foxman

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 2 pooled it
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 2 syntheses or guidelines pooled it, 262 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in immunology · 2021
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Exposure tobioRxiv : the preprint server for biology · 2026
    Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anchi WuDepartment of Laboratory Medicine (A Wu BSE, V T Mihaylova PhD, Prof M L Landry MD, Prof E F Foxman MD), Department of Internal Medicine (Prof M L Landry), and Department of Immunobiology (A Wu, Prof E F Foxman), Yale University School of Medicine, New Haven, CT, USA.
Valia T MihaylovaDepartment of Laboratory Medicine (A Wu BSE, V T Mihaylova PhD, Prof M L Landry MD, Prof E F Foxman MD), Department of Internal Medicine (Prof M L Landry), and Department of Immunobiology (A Wu, Prof E F Foxman), Yale University School of Medicine, New Haven, CT, USA.
Marie L LandryDepartment of Laboratory Medicine (A Wu BSE, V T Mihaylova PhD, Prof M L Landry MD, Prof E F Foxman MD), Department of Internal Medicine (Prof M L Landry), and Department of Immunobiology (A Wu, Prof E F Foxman), Yale University School of Medicine, New Haven, CT, USA.
Ellen F FoxmanDepartment of Laboratory Medicine (A Wu BSE, V T Mihaylova PhD, Prof M L Landry MD, Prof E F Foxman MD), Department of Internal Medicine (Prof M L Landry), and Department of Immunobiology (A Wu, Prof E F Foxman), Yale University School of Medicine, New Haven, CT, USA.
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Medical Scientist Training ProgramT32GM136651 · NIGMS · YALE UNIVERSITY · PI BARBARA I KAZMIERCZAK · 2020 to 2026
$16.5M
Cell Death and Cross-Protection in Rhinovirus InfectionK08AI119139 · NIAID · YALE UNIVERSITY · PI FOXMAN, ELLEN FLESCHER · 2015 to 2019
$947k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS K08 AI119139NIGMS NIH HHS T32 GM007205NIGMS NIH HHS T32 GM136651
6 · The paper itself

Abstract

backgroundDuring the 2009 pandemic of an emerging influenza A virus (IAV; H1N1pdm09), data from several European countries indicated that the spread of the virus might have been interrupted by the annual autumn rhinovirus epidemic. We aimed to investigate viral interference between rhinovirus and IAV with use of clinical data and an experimental model.

methodsWe did a clinical data analysis and experimental infection study to investigate the co-occurrence of rhinovirus and IAV in respiratory specimens from adults (≥21 years) tested with a multiplex PCR panel at Yale-New Haven Hospital (CT, USA) over three consecutive winter seasons (Nov 1 to March 1, 2016-17, 2017-18, and 2018-19). We compared observed versus expected co-detections using data extracted from the Epic Systems electronic medical record system. To assess how rhinovirus infection affects subsequent IAV infection, we inoculated differentiated primary human airway epithelial cultures with rhinovirus (HRV-01A; multiplicity of infection [MOI] 0·1) or did mock infection. On day 3 post-infection, we inoculated the same cultures with IAV (H1N1 green fluorescent protein [GFP] reporter virus or H1N1pdm09; MOI 0·1). We used reverse transcription quantitative PCR or microscopy to quantify host cell mRNAs for interferon-stimulated genes (ISGs) on day 3 after rhinovirus or mock infection and IAV RNA on days 4, 5, or 6 after rhinovirus or mock infection. We also did sequential infection studies in the presence of BX795 (6 μM), to inhibit the interferon response. We compared ISG expression and IAV RNA and expression of GFP by IAV reporter virus.

findingsBetween July 1, 2016, and June 30, 2019, examination of 8284 respiratory samples positive for either rhinovirus (n=3821) or IAV (n=4463) by any test method was used to establish Nov 1 to March 1 as the period of peak virus co-circulation. After filtering for samples within this time frame meeting the inclusion criteria (n=13 707), there were 989 (7·2%) rhinovirus and 922 (6·7%) IAV detections, with a significantly lower than expected odds of co-detection (odds ratio 0·16, 95% CI 0·09-0·28). Rhinovirus infection of cell cultures induced ISG expression and protected against IAV infection 3 days later, resulting in an approximate 50 000-fold decrease in IAV H1N1pdm09 viral RNA on day 5 post-rhinovirus inoculation. Blocking the interferon response restored IAV replication following rhinovirus infection.

interpretationThese findings show that one respiratory virus can block infection with another through stimulation of antiviral defences in the airway mucosa, supporting the idea that interference from rhinovirus disrupted the 2009 IAV pandemic in Europe. These results indicate that viral interference can potentially affect the course of an epidemic, and this possibility should be considered when designing interventions for seasonal influenza epidemics and the ongoing COVID-19 pandemic.

fundingNational Institutes of Health, National Institute of General Medical Sciences, and the Yale Department of Laboratory Medicine.

Indexed as

COVID-19Influenza A virusInfluenza A Virus, H1N1 SubtypeData AnalysisHumansInterferonsPandemicsRhinovirusRNA, ViralUnited StatesInterferonsRNA, Viral

Identifiers

PMID33103132
PMCPMC7580833
OpenAlexW3083069389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.